Safety and Efficacy of Ezetimibe Added to Atorvastatin Versus Up Titration of Atorvastatin to 40 mg in Patients ≥65 Years of Age (from the ZETia in the ELDerly [ZETELD] Study)

American Journal of Cardiology

Volumn 105, Issue 5, 2010, Pages 656-663

  Zieve, Franklin ^a   Wenger, Nanette K ^b   Ben Yehuda, Ori ^c   Constance, Christian ^d   Bird, Steven ^e   Lee, Raymond ^e   Hanson, Mary E ^e   Jones Burton, Charlotte ^e   Tershakovec, Andrew M ^e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UCSD MEDICAL CENTER   (United States)

^d MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

AGED; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GALLBLADDER DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGE FACTORS; AGED; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; AZETIDINES; CHOLESTEROL, LDL; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PYRROLES; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 76849095375     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.10.029     Document Type: Article

References (19)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
2. JBS 2. Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 91 Suppl 5 (2005) v1-v52
3. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith Jr. S.C., Spertus J.A., and Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112 (2005) 2735-2752
4. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
5. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry: Drug-Induced Liver Injury: Premarketing Clinical Evaluation. 7507dft. 2007 Oct 12. Draft Guidance.
6. Liang K.Y., and Zeger S.L. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankya B 62 (2000) 134-148
7. Miettinen O., and Nurminen M. Comparative analysis of two rates. Stat Med 4 (1985) 213-226
8. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
9. Deedwania P., Stone P.H., Bairey Merz C.N., Cosin-Aguilar J., Koylan N., Luo D., Ouyang P., Piotrowicz R., Schenck-Gustafsson K., Sellier P., Stein J.H., Thompson P.L., and Tzivoni D. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation 115 (2007) 700-707
10. Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova R., Dallongeville J., De Backer G., Ebrahim S., Gjelsvik B., Herrmann-Lingen C., Hoes A., Humphries S., Knapton M., Perk J., Priori S.G., Pyorala K., Reiner Z., Ruilope L., Sans-Menendez S., Op Reimer W.S., Weissberg P., Wood D., Yarnell J., Zamorano J.L., Walma E., Fitzgerald T., Cooney M.T., Dudina A., Vahanian A., Camm J., De Caterina R., Dean V., Dickstein K., Funck-Brentano C., Filippatos G., Hellemans I., Kristensen S.D., McGregor K., Sechtem U., Silber S., Tendera M., Widimsky P., Zamorano J.L., Altiner A., Bonora E., Durrington P.N., Fagard R., Giampaoli S., Hemingway H., Hakansson J., Kjeldsen S.E., Larsen L., Mancia G., Manolis A.J., Orth-Gomer K., Pedersen T., Rayner M., Ryden L., Sammut M., Schneiderman N., Stalenhoef A.F., Tokgozoglu L., Wiklund O., and Zampelas A. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 14 Suppl 2 (2007) S1-S113
11. McPherson R., Frohlich J., Fodor G., Genest J., and Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement-recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 22 (2006) 913-927
12. Rahilly-Tierney C.R., Lawler E.V., Scranton R.E., and Michael G.J. Low-density lipoprotein reduction and magnitude of cardiovascular risk reduction. Prev Cardiol 12 (2009) 80-87
13. Cannon C.P., Steinberg B.A., Murphy S.A., Mega J.L., and Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 48 (2006) 438-445
14. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., and Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 44 (2004) 720-732
15. [Package Insert]. Zetia (Ezetimibe) (2008), Merck, Schering-Plough Pharmaceuticals, North Wales, Pennsylvania
16. [Package Insert]. Vytorin (Ezetimibe/Simvastatin) (2009), Merck, Schering-Plough Pharmaceuticals, North Wales, Pennsylvania
17. Robinson J.G., Davidson M., Shah A., Lin J., Neff D., DeLucca P., Tomassini J.E., Veltri E., and Tershakovec A.M. Efficacy and safety of ezetimibe and ezetimibe plus statin therapy in patients aged under 65, 65-74 and 75 years and older. Aging Health 3 (2007) 691-705
18. Pearson T., Denke M., McBride P., Battisti W.P., Brady W.E., and Palmisano J. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial. Am J Geriatr Pharmacother 3 (2005) 218-228
19. Lipka L., Sager P., Strony J., Yang B., Suresh R., and Veltri E. Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia. Drugs Aging 21 (2004) 1025-1032